Spectrum of Auto-antibodies in NMO and MOG Associated CNS Demyelination- The SANMAD Study

IF 2.9 4区医学 Q3 IMMUNOLOGY

Journal of neuroimmunology Pub Date : 2024-09-03 DOI:10.1016/j.jneuroim.2024.578446

M.M. Samim , Rupam Mandal , Jigil Joy , Debjyoti Dhar , Kshiteeja Jain , Anita Mahadevan , M. Netravathi

{"title":"Spectrum of Auto-antibodies in NMO and MOG Associated CNS Demyelination- The SANMAD Study","authors":"M.M. Samim , Rupam Mandal , Jigil Joy , Debjyoti Dhar , Kshiteeja Jain , Anita Mahadevan , M. Netravathi","doi":"10.1016/j.jneuroim.2024.578446","DOIUrl":null,"url":null,"abstract":"<div>This observational study explored coexisting organ-specific and non-organ-specific autoantibodies in Neuromyelitis optica spectrum disorder(NMOSD) and Myelin oligodendrocyte glycoprotein-IgG-1(MOG-IgG1) associated central nervous system demyelination(MOGAD) in a South Asian cohort from March 2017–2023. Of the 250 cases, 148 were MOGAD(82pediatric) and 102 were NMOSD(15 pediatric). 17.6 % tested positive for ≥1 antibody, with NMOSD showing a higher positivity rate (25.5 %) than MOGAD(12.2 %,p = 0.011). Double antibody positivity occurred more in NMOSD (5.9 %vs.MOGAD,1.4 %,p = 0.045). Three NMOSD cases had Sjogren syndrome with higher Anti-Ro-52 prevalence(12.7 %vs.4.1 %,p = 0.014). NMOSD patients with ≥1 antibody positivity had more constitutional symptoms (45.5 %vs.23.1 %,p = 0.045). Significant associations were found between NMOSD and female gender, having ≥1 antibody-positive status, and testing positive for Anti-Ro-52 and SS-A antibodies (p < 0.05).</div>","PeriodicalId":16671,"journal":{"name":"Journal of neuroimmunology","volume":"396 ","pages":"Article 578446"},"PeriodicalIF":2.9000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuroimmunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165572824001656","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This observational study explored coexisting organ-specific and non-organ-specific autoantibodies in Neuromyelitis optica spectrum disorder(NMOSD) and Myelin oligodendrocyte glycoprotein-IgG-1(MOG-IgG1) associated central nervous system demyelination(MOGAD) in a South Asian cohort from March 2017–2023. Of the 250 cases, 148 were MOGAD(82pediatric) and 102 were NMOSD(15 pediatric). 17.6 % tested positive for ≥1 antibody, with NMOSD showing a higher positivity rate (25.5 %) than MOGAD(12.2 %,p = 0.011). Double antibody positivity occurred more in NMOSD (5.9 %vs.MOGAD,1.4 %,p = 0.045). Three NMOSD cases had Sjogren syndrome with higher Anti-Ro-52 prevalence(12.7 %vs.4.1 %,p = 0.014). NMOSD patients with ≥1 antibody positivity had more constitutional symptoms (45.5 %vs.23.1 %,p = 0.045). Significant associations were found between NMOSD and female gender, having ≥1 antibody-positive status, and testing positive for Anti-Ro-52 and SS-A antibodies (p < 0.05).

查看原文本刊更多论文

NMO 和 MOG 相关中枢神经系统脱髓鞘的自身抗体谱--SANMAD 研究

这项观察性研究探讨了2017年3月至2023年南亚队列中神经脊髓炎视谱系障碍（NMOSD）和髓鞘少突胶质细胞糖蛋白-IgG-1（MOG-IgG1）相关中枢神经系统脱髓鞘（MOGAD）并存的器官特异性和非器官特异性自身抗体。在250例病例中，148例为MOGAD（82例儿科），102例为NMOSD（15例儿科）。17.6%的患者检测出≥1种抗体阳性，其中NMOSD的阳性率（25.5%）高于MOGAD（12.2%，P = 0.011）。双抗体阳性在 NMOSD 中出现较多（5.9%vs.MOGAD,1.4%,p = 0.045）。三例 NMOSD 患者患有 Sjogren 综合征，其抗 Ro-52 阳性率较高（12.7%vs.4.1%,p = 0.014）。抗体阳性率≥1 的 NMOSD 患者有更多的体质症状（45.5 %vs.23.1 %，p = 0.045）。研究发现，NMOSD 与女性性别、≥1 抗体阳性以及抗-Ro-52 和 SS-A 抗体检测阳性之间存在显著关联（p < 0.05）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of neuroimmunology 医学-免疫学

CiteScore

6.10

自引率

3.00%

发文量

154

审稿时长

37 days

期刊介绍： The Journal of Neuroimmunology affords a forum for the publication of works applying immunologic methodology to the furtherance of the neurological sciences. Studies on all branches of the neurosciences, particularly fundamental and applied neurobiology, neurology, neuropathology, neurochemistry, neurovirology, neuroendocrinology, neuromuscular research, neuropharmacology and psychology, which involve either immunologic methodology (e.g. immunocytochemistry) or fundamental immunology (e.g. antibody and lymphocyte assays), are considered for publication.